13th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”

August 18-20, 2017
The Langham Hotel
Pasadena, CA

Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center
SACRAMENTO, CA

City of Hope Comprehensive Cancer Center
DUAUTE, CA

University of Southern California/Norris Comprehensive Cancer Center
LOS ANGELES, CA

Stanford Cancer Institute Comprehensive Cancer Center
STANFORD, CA

Conference Chairs:
Primo Lara, Jr., M.D. | Edward Newman, Ph.D.

Educational Steering Committee:
David Gandara, M.D.
Shivaani Kummar, M.D.
Heinz-Josef Lenz, M.D.

Sponsored by:
THE MEDICAL EDUCATOR CONSORTIUM
PROGRAM CHAIRS

Primo Lara, Jr., M.D.
Acting Director, UCD Comprehensive Cancer Center
Professor of Medicine
University of California Davis School of Medicine
Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center

Edward Newman, Ph.D.
Associate Professor, Cancer Biology
Co-Leader of the Development Cancer Therapeutics Program
City of Hope Comprehensive Cancer Center Duarte, CA

STEERING COMMITTEE

David Gandara, M.D.
Professor of Medicine
University of California Davis School of Medicine
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Shivaani Kummar, M.D.
Professor of Medicine
Stanford University School of Medicine

Heinz-Josef Lenz, M.D.
Professor of Medicine and Preventive Medicine, Section Head of GI Oncology
University of Southern California, Keck School of Medicine
Associate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

DISTINGUISHED FACULTY

Afsaneh Barzi, MD, PhD
Assistant Professor of Medical Oncology
Department of Medicine
Division of Oncology
USC Norris Comprehensive Cancer Center Los Angeles, CA

Robert Chen, MD
Associate Professor
City of Hope Medical Center
Duarte, CA

Helen Chew, MD
Professor of Medicine, Division of Hematology/Oncology
UC Davis Comprehensive Cancer Center Sacramento, CA

Vincent Chung, MD, FACP
Associate Clinical Professor
City of Hope Department of Medical Oncology
Duarte, CA

A. Dimitrios Colevas, MD
Associate Professor of Medicine
Stanford University School of Medicine Stanford, CA

Mihaela Cristea, MD
Assistant Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center Duarte, CA

Tanya Dorff, MD
Assistant Professor
USC Keck School of Medicine
Norris Comprehensive Cancer Center Los Angeles, CA

Oliver Dorigo, MD, PhD
Professor
Stanford University School of Medicine Stanford, CA

Anthony El-Khoueiry, MD
Assistant Professor
USC California Keck School of Medicine
Norris Comprehensive Cancer Center Los Angeles, CA

Marwan Fakih, MD
Interim Chair and Professor, Medical Oncology and Therapeutics Research
Section Head, GI Medical Oncology
Co-Director, GI Cancers Program
City of Hope Comprehensive Cancer Center Duarte, CA

Paul Frankel, PhD
Staff Scientist, Division of Biostatistics
Department of Information Sciences
Beckman Research Institute, City of Hope Comprehensive Cancer Center Duarte, CA

David Gandara, MD
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center Sacramento, CA

Susan Groshen, PhD
Professor of Medicine and Director Biostatistics Core
USC Norris Comprehensive Cancer Center Los Angeles, CA

James Hu, MD
USC Norris Comprehensive Cancer Center Hematology/Oncology Services Los Angeles, CA

Brian Jonas, MD, PhD
Assistant Professor, Division of Hematology/Oncology
UC Davis School of Medicine Sacramento, CA

Kevin Kelly, MD, PhD
Associate Professor of Clinical Medicine
Assistant Medical Director of Clinical Investigations Support Office, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases University of Southern California Los Angeles, CA

Edward Kim, MD, PhD
Assistant Professor Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center Sacramento, CA

Mariana Koczywas, MD
Clinical Professor of Medicine
City of Hope Comprehensive Cancer Center Duarte, CA
Shivaani Kummar, MD  
Professor, Department of Medicine  
Director, Phase I Clinical Research Program  
Stanford University School of Medicine  
Stanford, CA  

Primo Lara, Jr., MD  
Professor of Medicine, Associate Director for Translational Research  
UC Davis Comprehensive Cancer Center  
Sacramento, CA  

Peter Lee, MD  
Billy Wilder Endowed Professor  
Chair, Department of Immuno-Oncology  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Heinz-Josef Lenz, MD, PhD  
Professor of Medicine and Preventive Medicine  
Section Head of GI Oncology  
University of Southern California  
Keck School of Medicine  
Associate Director for Clinical Research  
USC Norris Comprehensive Cancer Center  
Los Angeles, CA  

Jeffrey Longmate, PhD  
Professor and Director, Division of Biostatistics  
Department of Information Sciences  
Beckman Research Institute  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Philip Mack, PhD  
Associate Professor of Medicine, UC Davis School of Medicine  
Director, Cancer Molecular Pharmacology  
UC Davis Comprehensive Cancer Center  
Sacramento, CA  

Guido Marcucci, MD  
Professor of Medicine, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Kim Margolin, MD  
Professor of Medicine, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Erminia Massarelli, MD, PhD  
Associate Clinical Professor  
Department of Medical Oncology & Therapeutics Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Arta Monjazeb, MD, PhD  
Associate Professor  
Department of Radiology Oncology  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Edward Newman, PhD  
Associate Professor, Molecular Pharmacology  
Co-director, Analytical Pharmacology Core Facility  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Sumanta Pal, MD  
Assistant Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Mamta Parikh, MD, MS  
Assistant Professor  
Hematology & Oncology  
UC Davis Comprehensive Cancer Center  
Sacramento, CA  

Mark Pegram, MD  
Professor of Medicine  
Director of the Breast Cancer Program  
Co-Director of Molecular Therapeutic Program  
Stanford University  
Stanford, CA  

Christiane Querfeld, MD, PhD, FAAD  
Chief, Division of Dermatology  
Director, Cutaneous Lymphoma Program  
Assistant Professor/Dermatology  
Dermatopathology  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

David Quinn, MBBS, PhD  
Associate Professor and Head  
Section of GU Medical Oncology  
USC Keck School of Medicine Leader  
Developmental Therapeutics Program  
USC Norris Comprehensive Cancer Center  
Los Angeles, CA  

Sunil Reddy, MD  
Clinical Assistant Professor  
Medicine-Oncology  
Stanford Cancer Center  
Stanford, CA  

Jonathan Riess, MD  
Assistant Professor  
UC Davis School of Medicine  
Sacramento, CA  

Sarmad Sadeghi, MD, PhD  
Assistant Professor, University of Southern California  
Division of Oncology  
Norris Comprehensive Cancer Center  
Los Angeles, CA  

Ravi Salgia, MD, PhD  
Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Sandy Srinivas, MD  
Associate Professor  
Stanford University School of Medicine  
Stanford, CA  

Joseph Tuscano, MD  
Professor of Medicine, Division of Hematology and Oncology  
UC Davis School of Medicine  
UC Davis Comprehensive Cancer Center  
Sacramento, CA  

Przemyslaw Twardowski, MD  
Associate Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Jeff Weitzel, MD  
Professor of Oncology & Population Sciences  
Chief, Division of Clinical Cancer Genomics  
City of Hope Comprehensive Cancer Center  
Duarte, CA  

Yuan Yuan, MD, PhD  
Assistant Professor  
Department of Medical Oncology & Therapeutic Research  
City of Hope Comprehensive Cancer Center  
Duarte, CA
COURSE DESCRIPTION
This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES
After participating in this educational activity, you should be able to:

• Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of various tumor types, and identify specific opportunities for therapeutic intervention.

• Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of patients with cancer.

• Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of patients with cancer.

• Discuss new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE
This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT
This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently, improve patient outcomes.

ACCREDITATION
The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this live educational activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE
The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION
Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
### 13th Annual California Cancer Consortium Conference

**“Recent Advances and New Directions in Cancer Therapy”**

**FRIDAY, AUGUST 18th, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am</td>
<td>Registration &amp; Visit Exhibits</td>
</tr>
<tr>
<td>12:45 pm - 1:55 pm</td>
<td>Product Showcase Lunch (Non CME)</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Welcome and Introductions</td>
</tr>
</tbody>
</table>
|               | **Session 1: Everything Old is New Again: Targeting DNA Repair Pathways in Oncology**  
|               | *Chairs: Primo Lara (UC Davis) and Edward Newman (City of Hope)*  |
| 2:15 pm       | DNA Repair (PARP, Wee1, ATM, ATR, etc) as a Therapeutic Target       |
|               |  *Jeff Weitzel, City of Hope*                                       |
| 2:35 pm       | Question-and-Answer Session                                         |
| 2:40 pm       | BER Inhibitors (TRC102)                                              |
|               |  *Marianna Koczywas, City of Hope*                                   |
| 3:00 pm       | Question-and-Answer Session                                         |
| 3:05 pm       | ATR Inhibition (VX-970)                                              |
|               |  *Sumanta Pal, City of Hope*                                         |
| 3:25 pm       | Question-and-Answer Session                                         |
| 3:30 pm       | Novel Cytotoxics in Development                                      |
|               |  *Sarmad Sadeghi, USC*                                               |
| 3:50 pm       | Question-and-Answer Session                                         |
| 3:55 pm – 4:25 pm | Product Showcase (Non-CME )                                        |
| 4:25 pm – 4:40 pm | Refreshment Break; Visit Exhibits                                    |
|               | **Session 2: Clinical Trial Design**                                 |
|               | *Chairs: Susan Groshen (USC) and Paul Frankel (City of Hope)*        |
| 4:40 pm       | Design of Phase I Trials 101: Beyond Modified Fibonacci (CRM, TITE-CRM, etc)  
<p>|               |  <em>Shivaani Kummar, Stanford</em>                                         |
| 5:00 pm       | Question-and-Answer Session                                         |
| 5:05 pm       | Design of Phase 2 Trials 101: Promise and Pitfalls of Interim Analysis |
|               |  <em>Susan Groshen, USC</em>                                               |
| 5:25 pm       | Question-and-Answer Session                                         |
| 5:30 pm       | Statistical Considerations for Molecular Correlative Studies in Phase I and II Trials |
|               |  <em>Jeff Longmate, City of Hope</em>                                       |
| 5:50 pm       | Question-and-Answer Session                                         |
| 5:55 pm       | Roundtable Discussion                                               |
|               |  <em>Moderator: Edward Newman (City of Hope)</em>                           |
|               |  <em>Participants: Jeff Longmate, Paul Frankel, Susan Groshen, Shivaani Kummar</em> |
| 6:15 pm       | Adjourn for the Day                                                  |
| 6:30 pm – 7:30 pm | Welcome Reception                                                   |
| 7:30 pm – 9:00 pm | Product Showcase – Dinner (Non CME)                                  |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration, Breakfast, &amp; Visit Exhibits</td>
</tr>
<tr>
<td>6:45 am – 7:55 am</td>
<td>Breakfast &amp; Product Showcase (Non-CME)</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td><strong>Session 3: Cancer Immunotherapy</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair: Tanya Dorff (USC) and Mamta Parikh (UC Davis)</em></td>
</tr>
<tr>
<td>8:05 am</td>
<td>Overview of Immuno-Oncology</td>
</tr>
<tr>
<td></td>
<td><em>Arta Monjazeb, UC Davis</em></td>
</tr>
<tr>
<td>8:25 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Measuring Immune Response in Tumors</td>
</tr>
<tr>
<td></td>
<td><em>Peter Lee, City of Hope</em></td>
</tr>
<tr>
<td>8:50 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td></td>
<td><strong>Session 4: Malignant Melanoma</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair: Edward Newman (City of Hope) and Christiane Querfeld (City of Hope)</em></td>
</tr>
<tr>
<td>8:55 am</td>
<td>State of the Art: Immunotherapy</td>
</tr>
<tr>
<td></td>
<td><em>Kim Margolin, City of Hope</em></td>
</tr>
<tr>
<td>9:15 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>9:20 am</td>
<td>State of the Art: Targeted Therapies (BRAF, etc)</td>
</tr>
<tr>
<td></td>
<td><em>Sunil Reddy, Stanford</em></td>
</tr>
<tr>
<td>9:40 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>9:45 am – 10:30 am</td>
<td>Refreshment Break; Visit Exhibits</td>
</tr>
<tr>
<td>9:55 am – 10:25 am</td>
<td>Product Showcase (Non-CME)</td>
</tr>
<tr>
<td></td>
<td><strong>Session 5: Lung Cancers</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Erminia Massarelli (City of Hope) and Jonathan Riess (UC Davis)</em></td>
</tr>
<tr>
<td>10:30 am</td>
<td>Evolution and Increasing Complexity of Therapeutic Decision-Making in Advanced NSCLC</td>
</tr>
<tr>
<td></td>
<td><em>David Gandara, UC Davis</em></td>
</tr>
<tr>
<td>10:50 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>10:55 am</td>
<td>Small Cell Lung Cancer: State of the Art 2017</td>
</tr>
<tr>
<td></td>
<td><em>Ravi Salgia, City of Hope</em></td>
</tr>
<tr>
<td>11:15 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>11:20 am</td>
<td>EGFR Inhibitors in Lung Cancer</td>
</tr>
<tr>
<td></td>
<td><em>Jonathan Riess, UC Davis</em></td>
</tr>
<tr>
<td>11:40 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>11:45 am</td>
<td>ALK, MET, RET, NTRK Inhibitors in Lung Cancer</td>
</tr>
<tr>
<td></td>
<td><em>&lt;TBA&gt;</em></td>
</tr>
<tr>
<td>12:05 pm</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>12:10 pm</td>
<td>Lunch Break, Product Showcase, Visit Exhibits</td>
</tr>
<tr>
<td>12:20 pm – 1:20 pm</td>
<td>Product Showcase (Non-CME)</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>Visit Exhibits</td>
</tr>
</tbody>
</table>
CONFERENCE AGENDA

Session 6: Hematologic Malignancies
Chair: Guido Marcucci (City of Hope) and Joseph Tuscano (UC Davis)

1:30 pm  New Developments in Acute Lymphocytic Leukemia
Brian Jonas, UC Davis

1:50 pm  Question-and-Answer Session

1:55 pm  New Developments in Acute Myeloid Leukemia
Kevin Kelly, USC

2:15 pm  Question-and-Answer Session

2:20 pm  State of the Art: Malignant Lymphomas
Robert Chen, City of Hope

2:40 pm  Question and Answer Session

2:45 pm  New Developments in Plasma Cell Dyscrasias
Joseph Tuscano, UC Davis

3:05 pm  Question and Answer Session

3:10 pm – 3:20 pm  Refreshment break, Visit Exhibits

Session 7: Genitourinary Malignancies
Chairs: Mamta Parikh (UC Davis) and Samrad Sadeghi (USC)

3:20 pm  Castration Resistant Prostate Cancer
Przemyslaw Twardowski, City of Hope

3:40 pm  Question-and-Answer Session

3:45 pm  Renal Cell Carcinoma
Sandya Srinivas, Stanford

4:05 pm  Question-and-Answer Session

4:10 pm  Advances in Urothelial Cancer
David Quinn, USC

4:30 pm  Question and Answer Session

Session 8: Gastrointestinal Malignancies
Chairs: Vincent Chung (City of Hope) and Afsaneh Barzi (USC)

4:35 pm  New Developments in Esophagogastric and Pancreatic Cancers
Edward Kim, UC Davis

4:55 pm  Question-and-Answer Session

5:00 pm  New Developments in Colorectal Cancer
Marwan Fakih, City of Hope

5:20 pm  Question-and-Answer Session

5:25 pm  Update on Immunotherapy in GI Cancer
Anthony El-Khoueiry, USC

5:45 pm  Question-and-Answer Session

5:50 pm  Adjourn for the Day
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 9: Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10 am</td>
<td>Adjuvant Therapy in Breast Cancer: State of the Art&lt;br&gt;&lt;i&gt;Mark Pegram, Stanford&lt;/i&gt;</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>8:55 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>9:00 am – 9:45 am</td>
<td>Refreshment Break &amp; Visit Exhibits</td>
</tr>
<tr>
<td>9:10 am – 9:40 am</td>
<td>Product Showcase (Non-CME)</td>
</tr>
</tbody>
</table>

**Session 9: Breast Cancer**<br>
Chair: Yuan Yuan (City of Hope) and Helen Chew (UC Davis)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 10: Solid Tumors, New Therapeutics, and New Diagnostics</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 am</td>
<td>Head and Neck Cancer: New Developments&lt;br&gt;&lt;i&gt;A. Dimitrios Colevas, Stanford&lt;/i&gt;</td>
</tr>
<tr>
<td>10:05 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>10:10 am</td>
<td>Soft Tissue Sarcoma: Evolving Standards of Care&lt;br&gt;&lt;i&gt;James Hu, USC&lt;/i&gt;</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>10:35 am</td>
<td>Gynecologic Malignancies: New Approaches in 2017&lt;br&gt;&lt;i&gt;Mihaela Cristea, City of Hope&lt;/i&gt;</td>
</tr>
<tr>
<td>10:55 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Cell Therapy for Gynecologic Cancers&lt;br&gt;&lt;i&gt;Oliver Dorigo, Stanford&lt;/i&gt;</td>
</tr>
<tr>
<td>11:20 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>11:25 am</td>
<td>Circulating Tumor DNA: Clinical Applications&lt;br&gt;&lt;i&gt;Philip Mack, UC Davis&lt;/i&gt;</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Question-and-Answer Session</td>
</tr>
<tr>
<td>11:50 am</td>
<td>Closing and Adjourn</td>
</tr>
</tbody>
</table>
The Langham Hotel, Pasadena has been recognized with numerous accolades and awards from some of the top luxury hotel, meetings, dining and leisure travel publications in the world. The Los Angeles’ original getaway. Experience the iconic landmark hotel located in charming Pasadena, just minutes from Downtown.

Historical Property tours are offered daily at 2:00pm, led by our Service Stylists; please meet in the Lobby. Tours are also pre-reservable through our Concierge Desk at (626) 568-3900, or download a self-guided Historical Property Tour. See over 100 years of Langham Huntington history by downloading our Historic Timeline.

The Langham is offering special rates during this conference of $219 ++ for Deluxe King accommodations. Cut off date to make reservations is July 17, 2017, after that date reservations are based on hotel availability.

FOR RESERVATION CONTACT the in-house reservation team at 1-800-591-7481 and reference the group name (California Cancer Conference) or group code (MEC081817).
13th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”
August 18-20, 2017, The Langham Hotel, Pasadena, CA
Register online at www.meccinc.com or fax to 305.675.2718

Registration Form

Name _______________________________________________ Degree ______________
Address _________________________________________________________________ 
Telephone (____) _______________ Fax (____) _____________________
Email Address _____________________________________________________________
Specialty ________________________________________________________________ 

TYPE OF PRACTICE:  ❑ Private       ❑ Academic
                  ❑ Hospital       ❑ Other

REGISTRATION FEE:          ❑ $175 Physician
                            ❑ $  90 Nurse, Nurse Practitioner, Resident, Fellow, Students, Non-physician researchers and staff (e.g., CRAs)
                            ❑ $300 Industry Professional

Refunds must be provided in writing prior to July 8th, 2017. A $50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

I authorize MECC to charge my credit card i/a/o $__________ for the registration of this course using the following credit card.

Name as it appears on the card _____________________________ Exp. Date ____________
Card number __________________________________________ CVV Code: ________
Authorized signature __________________________________________________________

For those requiring special assistance, contact MECC at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2017
13th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

"Recent Advances and New Directions in Cancer Therapy"

August 18-20, 2017

The Langham Hotel, Pasadena, CA